Global Ticagrelor Market 2022 - Snapshot

August 2022 | 37 pages | ID: GE951D74F23BEN
Gen Consulting Company

Abstracts

The global ticagrelor market was estimated at USD 1,422 million in 2021 and is expected to hit USD 2,254 million by 2028, registering a CAGR of 6.8% from 2022 to 2028 as per the latest report by Gen Consulting Company.

This industry report offers market estimates of the global market, followed by a detailed analysis of the dosage, route of administration, application, end user, and region. The global market data on ticagrelor can be segmented by dosage: 90mg, 60mg. Ticagrelor market is further segmented by route of administration: nasogastric tube, oral. Based on application, the ticagrelor market is segmented into: acute coronary syndrome, cardiac surgery. On the basis of end user, the ticagrelor market also can be divided into: ambulatory surgery centers (ASCs), hospitals & clinics, others. Ticagrelor market by region is categorized into: North America, Asia Pacific, Europe, Rest of the World (ROW).

The competitive landscape of the market is highly consolidated and dominated by key players such as AstraZeneca plc.

The data-centric report focuses on market trends, status and outlook for segments. With comprehensive market assessment across the major geographies, the report is a valuable asset for the existing players, new entrants and the future investors.

Why buy this report?

• Get a detailed picture of the Global Ticagrelor Market
• Identify segments/areas to invest in over the forecast period in the Global Ticagrelor Market
• Understand the competitive environment, the market’s leading players
• The market estimate for ease of analysis across scenarios in Excel format.
• Strategy consulting and research support for three months.
• Print authentication provided for the single-user license.

Contents

PART 1. SUMMARY

PART 2. INTRODUCTION

Study period
Geographical scope
Market segmentation

PART 3. TICAGRELOR MARKET OVERVIEW

PART 4. MARKET BREAKDOWN BY DOSAGE

90mg
60mg

PART 5. MARKET BREAKDOWN BY ROUTE OF ADMINISTRATION

Nasogastric tube
Oral

PART 6. MARKET BREAKDOWN BY APPLICATION

Acute coronary syndrome
Cardiac surgery

PART 7. MARKET BREAKDOWN BY END USER

Ambulatory surgery centers (ASCs)
Hospitals & clinics
Others

PART 8. MARKET BREAKDOWN BY REGION

North America
Asia Pacific
Europe
Rest of the World (ROW)

PART 9. KEY COMPANIES

AstraZeneca plc

PART 10. METHODOLOGY